Piperazine → HCID 58346710, compound

HRID 222026Notes

Reaction equation

CS(O[CH2:6][CH2:7][N:8]1[C:16]2[CH2:15][CH2:14][C:13]3[C:17]4[C:23]([NH:24][C:25]5[CH:30]=[CH:29][C:28]([F:31])=[C:27]([Cl:32])[CH:26]=5)=[N:22][CH:21]=[N:20][C:18]=4[S:19][C:12]=3[C:11]=2[CH:10]=[N:9]1)(=O)=O.[NH:33]1[CH2:38][CH2:37][NH:36][CH2:35][CH2:34]1.C(N(C(C)C)CC)(C)C>CN(C=O)C.O>[Cl:32][C:27]1[CH:26]=[C:25]([NH:24][C:23]2[N:22]=[CH:21][N:20]=[C:18]3[S:19][C:12]4[C:11]5[CH:10]=[N:9][N:8]([CH2:7][CH2:6][N:33]6[CH2:38][CH2:37][NH:36][CH2:35][CH2:34]6)[C:16]=5[CH2:15][CH2:14][C:13]=4[C:17]=23)[CH:30]=[CH:29][C:28]=1[F:31]

Participants

Conditions

Temperature: 80 °C

Procedure

2-{6-[(3-chloro-4-fluorophenyl)amino]-4,5-dihydro-3H-pyrimido[5′,4′:4,5]thieno[2,3-e]indazol-3-yl}ethyl methanesulfonate (80 mg, 0.1 mmol), piperazine (25.1 mg, 0.29 mmol) and diisopropylethylamine (25 mg, 0.19 mmol) were mixed in 2 mL DMF. The reaction mixture was stirred at 80° C. for 16 h. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layer was concentrated under reduced pressure and purified by prep HPLC. The combined fractions were treated with saturated Na2CO3 and dried to afford free base product N-(3-chloro-4-fluorophenyl)-3-(2-piperazin-1-ylethyl)-4,5-dihydro-3H-pyrimido[5′,4′:4,5]thieno[2,3-e]indazol-6-amine (18.8 mg, 40%). 1H-NMR (DMSO-d6) δ 8.65 (broad s, 1H), 8.30 (s, 1H), 7.86 (dd, 1H), 7.60 (s, 1H), 7.56 (m, 1H), 7.35 (t, 1H), 4.19 (t, 2H), 4.34 (t, 2H), 3.20 (broad, 1H), 3.08 (t, 2H), 2.62 (m, 6H), 2.31 (m, 4H). LCMS RT=2.35 min, [M+H]+=484.1

Workup

extractionextracted with EtOAc
concentrationThe combined organic layer was concentrated under reduced pressure
custompurified by prep HPLC
additionThe combined fractions were treated with saturated Na2CO3
customdried

Sources & evidence

ORD record: ord-ff4c508f13e94600a6c23690b31f34df
Source dataset: uspto-grants-2012_06
DOI: 10.6084/m9.figshare.5104873.v1
Patent number: US08207172B2

Reaction notes

Loading…